Among them, PTC patients with high expression of CPSF2 had a higher risk of recurrence [43], high expression of KPNA-1 was associated with tamoxifen resistance and metastasis in breast cancer patients [44], KPNA-4 can be used as a biomarker for diagnosis and prognosis of hepatocellular carcinoma [45], and can also promote the metastasis of prostate cancer [46], and PAK2 can promote the migration and proliferation of salivary adenoid cystic carcinoma [47]. Here, KPNA4 is linked to breast carcinoma.